269 related articles for article (PubMed ID: 28552796)
21. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.
Tiedje V; Ting S; Herold T; Synoracki S; Latteyer S; Moeller LC; Zwanziger D; Stuschke M; Fuehrer D; Schmid KW
Oncotarget; 2017 Jun; 8(26):42613-42620. PubMed ID: 28489587
[TBL] [Abstract][Full Text] [Related]
22. Molecular therapeutics for anaplastic thyroid cancer.
Pozdeyev N; Rose MM; Bowles DW; Schweppe RE
Semin Cancer Biol; 2020 Apr; 61():23-29. PubMed ID: 31991166
[TBL] [Abstract][Full Text] [Related]
23. EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer.
Masudo K; Suganuma N; Nakayama H; Oshima T; Rino Y; Iwasaki H; Matsuzu K; Sugino K; Ito K; Kondo T; Nakamura Y; Yoshihara M; Masuda M; Miyagi Y
In Vivo; 2018; 32(1):25-31. PubMed ID: 29275295
[TBL] [Abstract][Full Text] [Related]
24. The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.
Kasaian K; Wiseman SM; Walker BA; Schein JE; Zhao Y; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
BMC Cancer; 2015 Dec; 15():984. PubMed ID: 26680454
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel therapeutic targets in anaplastic thyroid carcinoma using functional genomic mRNA-profiling: Paving the way for new avenues?
Jonker PK; van Dam GM; Oosting SF; Kruijff S; Fehrmann RS
Surgery; 2017 Jan; 161(1):202-211. PubMed ID: 27865593
[TBL] [Abstract][Full Text] [Related]
26. Poorly differentiated and anaplastic thyroid cancer.
Patel KN; Shaha AR
Cancer Control; 2006 Apr; 13(2):119-28. PubMed ID: 16735986
[TBL] [Abstract][Full Text] [Related]
27. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of
Ibrahimpasic T; Xu B; Landa I; Dogan S; Middha S; Seshan V; Deraje S; Carlson DL; Migliacci J; Knauf JA; Untch B; Berger MF; Morris L; Tuttle RM; Chan T; Fagin JA; Ghossein R; Ganly I
Clin Cancer Res; 2017 Oct; 23(19):5970-5980. PubMed ID: 28634282
[No Abstract] [Full Text] [Related]
28. Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer.
Li W; Li Y; Li J; Pang H
Technol Cancer Res Treat; 2023; 22():15330338231169870. PubMed ID: 37122242
[TBL] [Abstract][Full Text] [Related]
29. Molecular Biomarkers of Anaplastic Thyroid Carcinoma.
Bozorg-Ghalati F; Hedayati M
Curr Mol Med; 2017; 17(3):181-188. PubMed ID: 28828971
[TBL] [Abstract][Full Text] [Related]
30. New Insights into Immune Cells and Immunotherapy for Thyroid Cancer.
Tao Y; Li P; Feng C; Cao Y
Immunol Invest; 2023 Nov; 52(8):1039-1064. PubMed ID: 37846977
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of a hobnail pattern in papillary, poorly differentiated, and anaplastic thyroid carcinoma: a possible manifestation of high-grade transformation.
Amacher AM; Goyal B; Lewis JS; El-Mofty SK; Chernock RD
Am J Surg Pathol; 2015 Feb; 39(2):260-5. PubMed ID: 25321328
[TBL] [Abstract][Full Text] [Related]
32. Clonal evolution analysis of paired anaplastic and well-differentiated thyroid carcinomas reveals shared common ancestor.
Dong W; Nicolson NG; Choi J; Barbieri AL; Kunstman JW; Abou Azar S; Knight J; Bilguvar K; Mane SM; Lifton RP; Korah R; Carling T
Genes Chromosomes Cancer; 2018 Dec; 57(12):645-652. PubMed ID: 30136351
[TBL] [Abstract][Full Text] [Related]
33. Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.
Gómez Sáez JM; Jiménez-Fonseca P; Santamaría Sandi J; Capdevila Castillón J; Navarro González E; Zafón Llopis C; Ramón Y Cajal Asensio T; Riesco Eizaguirre G; Grande Pulido E; Galofré Ferrater JC
Endocrinol Nutr; 2015 Mar; 62(3):e15-22. PubMed ID: 25583658
[TBL] [Abstract][Full Text] [Related]
34. Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.
von Roemeling CA; Copland JA
Expert Opin Ther Targets; 2016; 20(2):159-66. PubMed ID: 26414044
[TBL] [Abstract][Full Text] [Related]
35. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
[TBL] [Abstract][Full Text] [Related]
36. Anaplastic thyroid cancer.
Ranganath R; Shah MA; Shah AR
Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):387-91. PubMed ID: 26313900
[TBL] [Abstract][Full Text] [Related]
37. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
von Roemeling CA; Marlow LA; Pinkerton AB; Crist A; Miller J; Tun HW; Smallridge RC; Copland JA
J Clin Endocrinol Metab; 2015 May; 100(5):E697-709. PubMed ID: 25675381
[TBL] [Abstract][Full Text] [Related]
38. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
39. Genetically engineered suicide gene in mesenchymal stem cells using a Tet-On system for anaplastic thyroid cancer.
Kalimuthu S; Oh JM; Gangadaran P; Zhu L; Lee HW; Jeon YH; Jeong SY; Lee SW; Lee J; Ahn BC
PLoS One; 2017; 12(7):e0181318. PubMed ID: 28727740
[TBL] [Abstract][Full Text] [Related]
40. Mutations of genes including DNMT3A detected by next-generation sequencing in thyroid cancer.
Guo LC; Zhu WD; Ma XY; Ni H; Zhong EJ; Shao YW; Yu J; Gu DM; Ji SD; Xu HD; Ji C; Yang JM; Zhang Y
Cancer Biol Ther; 2019; 20(3):240-246. PubMed ID: 30252567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
